[Long-term success after catheter ablation of atrial fibrillation].
Langzeiterfolg nach Vorhofflimmerablation.
Arrhythmia-free survival
Long-term outcome
Outcome predictors
Pulmonary vein isolation
Sinus rhythm
Journal
Herzschrittmachertherapie & Elektrophysiologie
ISSN: 1435-1544
Titre abrégé: Herzschrittmacherther Elektrophysiol
Pays: Germany
ID NLM: 9425873
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
13
07
2023
accepted:
27
09
2023
medline:
28
11
2023
pubmed:
21
10
2023
entrez:
20
10
2023
Statut:
ppublish
Résumé
Ablation is an established treatment option for atrial fibrillation (AF) and is associated with convincing success rates and a reasonable safety profile. Ablation strategies going beyond pulmonary vein isolation in patients with chronic forms of AF are less well established and reproducible. Especially in patients with progressed AF forms multiple ablation procedures might be mandatory to achieve reasonable clinical success. An early ablation strategy might stop or prolong the progress from paroxysmal to persistent AF. In addition, ablation is more effective than drug-based treatment and comparably safe. Long-term success rates after a single and after multiple ablation procedures in paroxysmal AF are reported with 60-70% and up to 80%, while success rates in persistent or long-standing persistent AF are less favorable (single procedure 40-50%, multiple procedures 70%). However, currently non-recurrence of AF is the most established but potentially not the best endpoint. The burden of AF after ablation as assessed by novel monitoring modalities might gain further clinical importance. Die aktuelle Datenlage zur langfristigen Effektivität der Vorhofflimmerablation ist umfangreich und limitiert zugleich. Die Pulmonalvenenisolation (PVI) ist dabei der einzige etablierte Endpunkt mit reproduzierbarer Wirksamkeit. Definierte und in ihrer Effektivität reproduzierbare Therapiestrategien für Patienten mit fortgeschrittenen Formen von Vorhofflimmern fehlen bislang. Für Patienten mit persistierendem Vorhofflimmern und fortgeschrittenem Substrat müssen mehrere Eingriffe mit z. T. komplexeren Ablationsstrategien in Betracht gezogen werden, um die Wahrscheinlichkeit von stabilem Sinusrhythmus zu erhöhen. Die Langzeiterfolgsraten nach einem einzelnen Eingriff werden für Patienten mit paroxysmalem Vorhofflimmern mit 60–70 % und nach wiederholten Eingriffen mit bis zu 80 % angegeben. Die Erfolgsraten bei persistierendem oder langanhaltend persistierendem Vorhofflimmern sind weniger überzeugend (Primäreingriff: 40–50 %, multiple Eingriffe: ca. 70 %). Daher ist eine frühzeitige Katheterablation von Vorhofflimmern zu empfehlen, um den Progress der Erkrankung und des atrialen Substrats aufzuhalten. Darüber hinaus ist sie der medikamentösen Therapie hinsichtlich der Effektivität überlegen.
Autres résumés
Type: Publisher
(ger)
Die aktuelle Datenlage zur langfristigen Effektivität der Vorhofflimmerablation ist umfangreich und limitiert zugleich. Die Pulmonalvenenisolation (PVI) ist dabei der einzige etablierte Endpunkt mit reproduzierbarer Wirksamkeit. Definierte und in ihrer Effektivität reproduzierbare Therapiestrategien für Patienten mit fortgeschrittenen Formen von Vorhofflimmern fehlen bislang. Für Patienten mit persistierendem Vorhofflimmern und fortgeschrittenem Substrat müssen mehrere Eingriffe mit z. T. komplexeren Ablationsstrategien in Betracht gezogen werden, um die Wahrscheinlichkeit von stabilem Sinusrhythmus zu erhöhen. Die Langzeiterfolgsraten nach einem einzelnen Eingriff werden für Patienten mit paroxysmalem Vorhofflimmern mit 60–70 % und nach wiederholten Eingriffen mit bis zu 80 % angegeben. Die Erfolgsraten bei persistierendem oder langanhaltend persistierendem Vorhofflimmern sind weniger überzeugend (Primäreingriff: 40–50 %, multiple Eingriffe: ca. 70 %). Daher ist eine frühzeitige Katheterablation von Vorhofflimmern zu empfehlen, um den Progress der Erkrankung und des atrialen Substrats aufzuhalten. Darüber hinaus ist sie der medikamentösen Therapie hinsichtlich der Effektivität überlegen.
Identifiants
pubmed: 37863850
doi: 10.1007/s00399-023-00972-1
pii: 10.1007/s00399-023-00972-1
doi:
Types de publication
English Abstract
Journal Article
Review
Langues
ger
Sous-ensembles de citation
IM
Pagination
286-290Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.
Références
Calkins H, Hindricks G, Cappato R, Kim YH, Saad EB, Aguinaga L et al (2017) 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: executive summary. Heart Rhythm 14(10):e445–e494
doi: 10.1016/j.hrthm.2017.07.009
pubmed: 31631881
Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstrom-Lundqvist C et al (2020) 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J
Haissaguerre M, Jais P, Shah DC, Takahashi A, Hocini M, Quiniou G et al (1998) Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 339(10):659–666
doi: 10.1056/NEJM199809033391003
pubmed: 9725923
Ganesan AN, Shipp NJ, Brooks AG, Kuklik P, Lau DH, Lim HS et al (2013) Long-term outcomes of catheter ablation of atrial fibrillation: a systematic review and meta-analysis. J Am Heart Assoc 2(2):e4549
doi: 10.1161/JAHA.112.004549
pubmed: 23537812
pmcid: 3647286
Brooks S, Metzner A, Wohlmuth P, Lin T, Wissner E, Tilz R et al (2018) Insights into ablation of persistent atrial fibrillation: lessons from 6‑year clinical outcomes. J Cardiovasc Electrophysiol 29(2):257–263
doi: 10.1111/jce.13401
pubmed: 29216412
Tilz RR, Rillig A, Thum AM, Arya A, Wohlmuth P, Metzner A et al (2012) Catheter ablation of long-standing persistent atrial fibrillation: 5‑year outcomes of the Hamburg Sequential Ablation Strategy. J Am Coll Cardiol 60(19):1921–1929
doi: 10.1016/j.jacc.2012.04.060
pubmed: 23062545
Clarnette JA, Brooks AG, Mahajan R, Elliott AD, Twomey DJ, Pathak RK et al (2018) Outcomes of persistent and long-standing persistent atrial fibrillation ablation: a systematic review and meta-analysis. Europace 20(FI_3):f366–f376
doi: 10.1093/europace/eux297
pubmed: 29267853
Gaita F, Scaglione M, Battaglia A, Matta M, Gallo C, Galata M et al (2018) Very long-term outcome following transcatheter ablation of atrial fibrillation. Are results maintained after 10 years of follow up? Europace 20(3):443–450
doi: 10.1093/europace/eux008
pubmed: 28340043
Nery PB, Belliveau D, Nair GM, Bernick J, Redpath CJ, Szczotka A et al (2016) Relationship between pulmonary vein Reconnection and atrial fibrillation recurrence: a systematic review and meta-analysis. JACC Clin Electrophysiol 2(4):474–483
doi: 10.1016/j.jacep.2016.02.003
pubmed: 29759868
Ouyang F, Antz M, Ernst S, Hachiya H, Mavrakis H, Deger FT et al (2005) Recovered pulmonary vein conduction as a dominant factor for recurrent atrial tachyarrhythmias after complete circular isolation of the pulmonary veins: lessons from double lasso technique. Circulation 111(2):127–135
doi: 10.1161/01.CIR.0000151289.73085.36
pubmed: 15623542
Kuck KH, Albenque JP, Chun KJ, Furnkranz A, Busch M, Elvan A et al (2019) Repeat ablation for atrial fibrillation recurrence post Cryoballoon or Radiofrequency ablation in the FIRE AND ICE trial. Circ Arrhythm Electrophysiol 12(6):e7247
doi: 10.1161/CIRCEP.119.007247
pubmed: 31693319
Lin D, Santangeli P, Zado ES, Bala R, Hutchinson MD, Riley MP et al (2015) Electrophysiologic findings and long-term outcomes in patients undergoing third or more catheter ablation procedures for atrial fibrillation. J Cardiovasc Electrophysiol 26(4):371–377
doi: 10.1111/jce.12603
pubmed: 25534677
Sotomi Y, Inoue K, Ito N, Kimura R, Toyoshima Y, Masuda M et al (2013) Incidence and risk factors for very late recurrence of atrial fibrillation after radiofrequency catheter ablation. Europace 15(11):1581–1586
doi: 10.1093/europace/eut076
pubmed: 23608030
Erhard N, Mauer T, Ouyang F, Sciacca V, Rillig A, Reissmann B et al (2023) Mechanisms of late arrhythmia recurrence after initially successful pulmonary vein isolation in patients with atrial fibrillation. Pacing Clin Electrophysiol 46(2):161–168
doi: 10.1111/pace.14656
pubmed: 36588339
Fink T, Schluter M, Heeger CH, Lemes C, Maurer T, Reissmann B et al (2018) Combination of left atrial appendage isolation and ligation to treat Nonresponders of pulmonary vein isolation. JACC Clin Electrophysiol 4(12):1569–1579
doi: 10.1016/j.jacep.2018.09.022
pubmed: 30573121
Marrouche NF, Wilber D, Hindricks G, Jais P, Akoum N, Marchlinski F et al (2014) Association of atrial tissue fibrosis identified by delayed enhancement MRI and atrial fibrillation catheter ablation: the DECAAF study. JAMA 311(5):498–506
doi: 10.1001/jama.2014.3
pubmed: 24496537
Narayan SM, Baykaner T, Clopton P, Schricker A, Lalani GG, Krummen DE et al (2014) Ablation of rotor and focal sources reduces late recurrence of atrial fibrillation compared with trigger ablation alone: extended follow-up of the CONFIRM trial (conventional ablation for atrial fibrillation with or without focal impulse and rotor modulation). J Am Coll Cardiol 63(17):1761–1768
doi: 10.1016/j.jacc.2014.02.543
pubmed: 24632280
pmcid: 4008643
Fink T, Schluter M, Heeger CH, Lemes C, Maurer T, Reissmann B et al (2017) Stand-alone pulmonary vein isolation versus pulmonary vein isolation with additional substrate modification as index ablation procedures in patients with persistent and long-standing persistent atrial fibrillation: the randomized Alster-lost-AF trial (ablation at st. Georg hospital for long-standing persistent atrial fibrillation). Circ Arrhythm Electrophysiol 10(7)
Vogler J, Willems S, Sultan A, Schreiber D, Luker J, Servatius H et al (2015) Pulmonary vein isolation versus Defragmentation: the CHASE-AF clinical trial. J Am Coll Cardiol 66(24):2743–2752
doi: 10.1016/j.jacc.2015.09.088
pubmed: 26700836
Takigawa M, Takahashi A, Kuwahara T, Okubo K, Takahashi Y, Watari Y et al (2014) Long-term follow-up after catheter ablation of paroxysmal atrial fibrillation: the incidence of recurrence and progression of atrial fibrillation. Circ Arrhythm Electrophysiol 7(2):267–273
doi: 10.1161/CIRCEP.113.000471
pubmed: 24610740
Kerr CR, Humphries KH, Talajic M, Klein GJ, Connolly SJ, Green M et al (2005) Progression to chronic atrial fibrillation after the initial diagnosis of paroxysmal atrial fibrillation: results from the Canadian registry of atrial fibrillation. Am Heart J 149(3):489–496
doi: 10.1016/j.ahj.2004.09.053
pubmed: 15864238
de Vos CB, Pisters R, Nieuwlaat R, Prins MH, Tieleman RG, Coelen RJ et al (2010) Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis. J Am Coll Cardiol 55(8):725–731
doi: 10.1016/j.jacc.2009.11.040
pubmed: 20170808
Kuck KH, Lebedev DS, Mikhaylov EN, Romanov A, Geller L, Kalejs O et al (2021) Catheter ablation or medical therapy to delay progression of atrial fibrillation: the randomized controlled atrial fibrillation progression trial (ATTEST). Europace 23(3):362–369
doi: 10.1093/europace/euaa298
pubmed: 33330909
Andrade JG, Deyell MW, Macle L, Wells GA, Bennett M, Essebag V et al (2023) Progression of atrial fibrillation after Cryoablation or drug therapy. N Engl J Med 388(2):105–116
doi: 10.1056/NEJMoa2212540
pubmed: 36342178
Mark DB, Anstrom KJ, Sheng S, Piccini JP, Baloch KN, Monahan KH et al (2019) Effect of catheter ablation vs medical therapy on quality of life among patients with atrial fibrillation: the CABANA randomized clinical trial. JAMA 321(13):1275–1285
doi: 10.1001/jama.2019.0692
pubmed: 30874716
pmcid: 6450275
Kirchhof P, Camm AJ, Goette A, Brandes A, Eckardt L, Elvan A et al (2020) Early rhythm-control therapy in patients with atrial fibrillation. N Engl J Med 383(14):1305–1316
doi: 10.1056/NEJMoa2019422
pubmed: 32865375
Andrade JG, Wells GA, Deyell MW, Bennett M, Essebag V, Champagne J et al (2021) Cryoablation or drug therapy for initial treatment of atrial fibrillation. N Engl J Med 384(4):305–315
doi: 10.1056/NEJMoa2029980
pubmed: 33197159
Wazni OM, Dandamudi G, Sood N, Hoyt R, Tyler J, Durrani S et al (2021) Cryoballoon ablation as initial therapy for atrial fibrillation. N Engl J Med 384(4):316–324
doi: 10.1056/NEJMoa2029554
pubmed: 33197158
Ekanem E, Reddy VY, Schmidt B, Reichlin T, Neven K, Metzner A et al (2022) Multi-national survey on the methods, efficacy, and safety on the post-approval clinical use of pulsed field ablation (MANIFEST-PF). Europace 24(8):1256–1266
doi: 10.1093/europace/euac050
pubmed: 35647644
pmcid: 9435639
Packer DL, Mark DB, Robb RA, Monahan KH, Bahnson TD, Poole JE et al (2019) Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: the CABANA randomized clinical trial. JAMA 321(13):1261–1274
doi: 10.1001/jama.2019.0693
pubmed: 30874766
pmcid: 6450284
Marrouche NF, Brachmann J, Andresen D, Siebels J, Boersma L, Jordaens L et al (2018) Catheter ablation for atrial fibrillation with heart failure. N Engl J Med 378(5):417–427
doi: 10.1056/NEJMoa1707855
pubmed: 29385358
Verma A, Champagne J, Sapp J, Essebag V, Novak P, Skanes A et al (2013) Discerning the incidence of symptomatic and asymptomatic episodes of atrial fibrillation before and after catheter ablation (DISCERN AF): a prospective, multicenter study. JAMA Intern Med 173(2):149–156
doi: 10.1001/jamainternmed.2013.1561
pubmed: 23266597
Kuck KH, Furnkranz A, Chun KR, Metzner A, Ouyang F, Schluter M et al (2016) Cryoballoon or radiofrequency ablation for symptomatic paroxysmal atrial fibrillation: reintervention, rehospitalization, and quality-of-life outcomes in the FIRE AND ICE trial. Eur Heart J 37(38):2858–2865
doi: 10.1093/eurheartj/ehw285
pubmed: 27381589
pmcid: 5070448
Chen LY, Chung MK, Allen LA, Ezekowitz M, Furie KL, McCabe P et al (2018) Atrial fibrillation burden: moving beyond atrial fibrillation as a binary entity: a scientific statement from the American heart association. Circulation 137(20):e623–e644
doi: 10.1161/CIR.0000000000000568
pubmed: 29661944
pmcid: 8463258
Brachmann J, Sohns C, Andresen D, Siebels J, Sehner S, Boersma L et al (2021) Atrial Fibrillation Burden and Clinical Outcomes in Heart Failure: The CASTLE-AF Trial. JACC Clin Electrophysiol 7(5):594–603
doi: 10.1016/j.jacep.2020.11.021
pubmed: 33640355